FDA Panel Supports Ketek as Second-Line for CAP; Suggests Black Box
Executive Summary
Sanofi-Aventis' Ketek should not be the first-line treatment for community acquired pneumonia, members of an FDA advisory panel cautioned when they recommended continued marketing of the antibiotic for CAP
You may also be interested in...
Rx Industry Faces Wave of Personal Injury Suits; Avandia To Test Honed Skills
Some of the biggest names in product liability litigation will be flocking to a conference in Chicago July 13 to focus on one drug: Avandia. Mark Lanier, who won the largest jury verdict against Vioxx, is co-chairing the event. Other headliners include Christopher Seeger, a lead plaintiffs attorney in the federal Vioxx litigation, and Karen Barth Menzies, who has spearheaded dozens of cases against antidepressant products
Rx Industry Faces Wave of Personal Injury Suits; Avandia To Test Honed Skills
Some of the biggest names in product liability litigation will be flocking to a conference in Chicago July 13 to focus on one drug: Avandia. Mark Lanier, who won the largest jury verdict against Vioxx, is co-chairing the event. Other headliners include Christopher Seeger, a lead plaintiffs attorney in the federal Vioxx litigation, and Karen Barth Menzies, who has spearheaded dozens of cases against antidepressant products
Ketek Superiority Trials May Hold Key To Sales After Safety Relabeling
Sanofi-Aventis recently conducted superiority trials for its antibiotic Ketek, and the results could determine whether the drug bounces back from an FDA decision to withdraw two indications from the drug's label